Results 121 to 130 of about 19,767 (298)

The Molecular Pathogenesis of Pituitary Adenomas: An Update [PDF]

, 2013
Pituitary tumors represent the most common intracranial neoplasms accompanying serious morbidity through mass effects and inappropriate secretion of pituitary hormones. Understanding the etiology of pituitary tumorigenesis will facilitate the development
Jiang, Xiaobing, Zhang, Xun
core   +2 more sources

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma

Indian Journal of Endocrinology and Metabolism, 2017
Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare, Anurag R Lila, Rishikesh Patil, Milind Phadke, Prafulla Kerkar, Tushar Bandgar, Nalini S Shah   +6 more
doaj   +1 more source

Case Report: Multiple prolactinomas in a young man with Kallmann syndrome and familial hypocalciuric hypercalcemia [PDF]

, 2023
Mojca Jensterle, Andrej Janež, Tina Vipotnik Vesnaver, Maruša Debeljak, Nika Breznik, Katarina Trebušak Podkrajšek, Rok Herman, Eric Fliers, Tadej Battelino, Magdalena Avbelj Stefanija   +9 more
openalex   +1 more source

THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.

Endocrine Practice, 2019
Objectives To evaluate the effect of raloxifene on prolactin levels in addition to dopamine agonist (DA) therapy in patients with prolactinoma. Methods We conducted a retrospective chart review of 14 patients with prolactinoma on stable dose of DA for 6 ...
Chitra Choudhary, A. Hamrahian, J. Bena, P. Recinos, L. Kennedy, Georgiana Dobri   +5 more
semanticscholar   +1 more source

A study on the correlations of PRL levels with anxiety, depression, sleep, and self-efficacy in patients with prolactinoma

Frontiers in Endocrinology
PurposeThe purpose of this study was to explore the factors influencing PRL levels in patients with prolactinoma and to investigate the correlations between anxiety, depression, sleep, self-efficacy, and PRL levels.MethodsThis retrospective study ...
Xiaoju Miao, Xiaoju Miao, Zhongmin Fu, Zhongmin Fu, Xian Luo, Xian Luo, Jun Wang, Jun Wang, Lili Yuan, Lili Yuan, Shunjun Zhao, Shunjun Zhao, Yi Feng, Shiming Huang, Shunwu Xiao   +14 more
doaj   +1 more source

Mean platelet volume in patients with prolactinoma

Archives of Endocrinology and Metabolism, 2016
Objective Prolactin is a multifunctional pituitary hormone. The effect of prolactin on platelet activation is not well understood. Prolactinomas are the most common type of pituitary adenomas, and they are medically responsive to dopamine agonists. Mean
Abbas Ali Tam, Cafer Kaya, Hüsniye Başer, Reyhan Ersoy, Bekir Çakır   +4 more
doaj   +1 more source

Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas

Journal of the Endocrine Society, 2017
Pheochromocytomas are neuroendocrine tumors that can arise sporadically or be inherited as a familial disease, and they may occur in isolation or as part of a multitumor syndrome. Familial disease typically presents in younger patients with a higher risk
Kelly L. Roszko, Erica Blouch, M. Blake, J. Powers, A. Tischler, R. Hodin, P. Sadow, E. Lawson   +7 more
semanticscholar   +1 more source

Medical treatment of prolactinomas. [PDF]

, 2011
Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are hypogonadism, infertility and hyposexuality.
A Barlier, A Beckers, A Chattopadhyay, A Ciccarelli, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Di Sarno, A Di Sarno, A Klibanski, A Liuzzi, A Saveanu, A Wakil, A Zárate, AG Lania, AI McCormack, AM Colao, Annamaria Colao, AP Heaney, BM Biller, C Di Somma, C Ferrari, C Rasmussen, C Wang, CY Choong, D Cheung, D Dallabonzana, D McCall, DA De Luis, DA Sisam, DG Johnston, DG Johnston, E Delgrange, E Delgrange, E Delgrange, E Valassi, EJ Lee, F Andersohn, F Bogazzi, F Bogazzi, FF Casanueva, G Raverot, G Schettini, G Zada, GA Kaltsas, HE Turner, I Shimon, I Shimon, J Gorski, J Kharlip, J Schlechte, J Verhelst, J Webster, JC Williams, JJ Orrego, JK Devin, JM Wilson, JP Singh, JS Bevan, JW van't Verlaat, K Thapar, K Thapar, KJ Gräf, L Vilar, LB Nachtigall, LC Tan, LD George, LJ Hofland, M Biswas, M De Rosa, M De Rosa, M De Rosa, M Esteller, M Giusti, M Kars, M Kars, M Lafeber, M Muratori, M Ono, M Rocheville, M Steiger, MC Koppelman, MD Bronstein, ME Molitch, ML Vance, MP Gillam, MP Gillam, MS Huda, N Herring, OM Dekkers, P Fainstein Day, P Lancellotti, P Moriondo, PG Crosignani, PU Freda, R Homburg, R Schade, R Zanettini, RB Rothman, S Cannavò, S Ekeblad, S Karunakaran, S Mohammed, S Vallette, SG Ren, Silvia Savastano, SW Lamberts, SW Lamberts, T Mindermann, T Sabuncu, T Tan, V Goffin, VG Rasmussen, VQ Passos, W Winkelmann, WJ Jeffcoate, WS Maxson, Y Greenman   +131 more
core   +1 more source

Hiperprolactinemia em pacientes femininas: estudo de seis casos. [PDF]

, 1999
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Departamento de Tocoginecologia, Curso de Medicina, Florianópolis ...
Martins, Angelo Francisco
core  

Brief Report: AIP Mutation in Pituitary Adenomas in the 18th Century and Today [PDF]

, 2013
From New England Journal of Medicine, Volume 364, issue 1, p.43-50. Copyright © (2011) Massachusetts Medical Society. Reprinted with permission.Gigantism results when a growth hormone–secreting pituitary adenoma is present before epiphyseal fusion.
Abel, RL, Akker, SA, Atkinson, AB, Balding, DJ, Besser, GM, Burger, J, Chahal, HS, Ellard, Sian, Grossman, AB, Howlett, TA, Korbonits, M, Kumar, AV, Levy, MJ, Morrison, PJ, Orme, SM, Stals, K, Thomas, MG, Unterlander, M   +17 more
core   +1 more source